Recently, Morgan Stanley Capital International (MSCI), a leading global index provider, released its latest annual ESG (Environmental, Social, and Governance) ratings. Fosun Pharma ascended to an 'AA' rating, highlighting its exceptional performance in sustainable development, reflecting its leadership position within the domestic pharmaceutical industry and underscoring its ongoing advancements in ESG governance and execution.

For over 30 years since its establishment, Fosun Pharma has consistently prioritized sustainable development, publishing ESG and Sustainability Reports or Corporate Social Responsibility Reports for 17 consecutive years. Fosun Pharma has been recognized in multiple prestigious lists, including the 2024 China ESG 50 List (Forbes), the China ESG Listed Company Pioneers 100 (CCTV), and the China Best Managed Companies (Deloitte). Fosun Pharma was also listed on the 2025 Fortune China ESG Impact List, becoming the only Chinese pharmaceutical company featured, demonstrating broad societal recognition.

E: Green Development: Minimizing Carbon Footprint and Maximizing Efficiency

In 2024, Fosun Pharma reaffirmed its commitment to advancing its EHS (Environment, Health, and Safety) management system and remained dedicated to strategically identifying, evaluating, and addressing environmental challenges and opportunities associated with its business operations, striving to achieve a harmonious balance between creating economic value and promoting environmental sustainability. In 2024, Fosun Pharma allocated approximately RMB 110 million towards upgrading and operating its environmental protection facilities. This initiative led to savings of 13.45 million kWh of electricity, 270,000 m³ of natural gas, and 7,307 tons of purchased steam, resulting in a reduction of 10,196 tons of carbon emissions. Furthermore, Fosun Pharma's photovoltaic systems generated over 14.58 million kWh of electricity, representing a nearly fourfold year-over-year increase. Comprehensive energy consumption intensity also decreased by 5.18%. By procuring 19.25 million kWh of green electricity, carbon emissions were further reduced by 10,332 tons, bringing the total reduction to 20,528 tons. At the same time, Fosun Pharma has upheld strict management of emissions, including exhaust gases, wastewater, and waste materials. In 2024, multiple pollution control indicators outperformed its interim targets.

Fosun Pharma continues to strengthen its systems across key areas such as innovation and R&D, product quality management, accessible healthcare, talent development, social responsibility, and supply chain governance.

Fosun Pharma is indicated to innovative R&D to address unmet clinical needs, striving to improve drug accessibility and affordability. Innovative products are consistently being launched in areas such as hematologic malignancies, breast cancer, and lung cancer, including Han Li Kang^®, China's first biosimilar; Han Qu You^®, the first domestically produced trastuzumab biosimilar; and Han Si Zhuang^®, the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer. In the field of rare diseases, by the end of 2024, Fosun Pharma had successfully launched 5 products, with 10 indications under development. In 2025, the company’s independently developed innovator drug, Fu Mai Ning^® was approved for two indications, addressing unmet medical needs in rare oncology and expanding therapeutic options for patients.

Globally, Fosun Pharma not only provides innovative therapies to patients worldwide but also actively supports healthcare system development in emerging markets. Through drug supply, technical training, and localized production, the company has continued to strengthen public health capacity in Africa. By the end of 2024, Fosun Pharma’s self-developed artesunate for injection had surpassed 400 million doses supplied globally, treating over 80 million severe malaria patients. In 2024 alone, the company held over 2,500 CME (Continuing Medical Education) events in Africa, training more than 41,000 healthcare professionals, significantly improving their professional capabilities.

In 2025, Fosun Pharma became an associate member of the PSCI (Pharmaceutical Supply Chain Initiative), actively aligning with international governance standards and committing to building a responsible value chain in collaboration with global partners.

Fosun Pharma actively embraces its social responsibility by aligning with the national rural revitalization strategy. Through the 'Fosun Pharma Health Care Initiative,' a dedicated public welfare fund, Fosun Pharma plays a significant role in the 'Rural Doctor Project' and has launched the 'Pink Blue Ribbon Charity Initiative' to support cervical and breast cancer screenings, thereby promoting and protecting the health of grassroots communities. Over the past three years, Fosun Pharma's cumulative charitable donations have exceeded RMB 300 million.

G: Effective Governance: Driving Sustainable Progress

Fosun Pharma has established an ESG governance structure, comprising the Board and the ESG Committee under the Board, the ESG Management Committee, and the ESG Working Group. This framework ensures effective oversight, scientific guidance, and strong support from the Board and senior management for the company’s sustainable development agenda. In 2020, the company formalized the Terms of Reference for the Board ESG Committee, clearly defining its responsibilities. Fosun Pharma also periodically reviews and adjusts its ESG governance in line with regulatory guidance and practical needs.

In 2024, aligning with the latest Shanghai Stock Exchange (SSE) Sustainability Reporting Guideline and the Hong Kong Stock Exchange (HKEX) ESG Reporting Guide, Fosun Pharma identified and assessed key ESG issues based on financial materiality and impact materiality, thereby improving the quality of ESG disclosures.

Furthermore, Fosun Pharma continuously enhancing its compliance and anti-corruption system, promoting ethical business practices across multiple dimensions-including anti-bribery and anti-corruption, employee rights protection, information security, and international trade compliance- to foster a transparent and integrity-driven governance environment. 

Looking ahead, Fosun Pharma will remain committed to its mission of "Better Health for Families Worldwide," further embedding ESG principles into its strategy and operations, and actively creating long-term sustainable value for the industry and society.